Synonyms: crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59
crovalimab is an approved drug (China NMPA, FDA & EMA (2024))
Compound class:
Antibody
Comment: Crovalimab (SKY59/RG6107) is a long-acting anti-C5 recycling monoclonal antibody [2,6]. The antibody is engineered to bind C5 in a pH-dependent manner. It binds strongly to C5 in the plasma, but in the acidic conditions within the endosome the antibody-C5 immune complex dissociates. The free antibody is re-cycled and can bind more plasma C5, to provide sustained complement inhibition. The C5 released in the endosome is trafficked to the lysosome for degradation. Crovalimab is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) [5] and Lupus nephritis.
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (China NMPA, FDA & EMA (2024)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10882 | crovalimab |
Synonyms ![]() |
crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59 |
Database Links ![]() |
|
GtoPdb PubChem SID | 483123338 |
Search PubMed clinical trials | crovalimab |
Search PubMed titles | crovalimab |
Search PubMed titles/abstracts | crovalimab |